Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) (EVER-RECODE)

Everolimus in Refractory Metastatic Colorectal Cancer With CDK12 Deficiency: A Prospective Multicenter Phase Ib/II Study (EVER-RECODE)

This is a prospective, open-label, multicenter, single-arm Phase Ib/II study evaluating the safety and preliminary efficacy of everolimus in patients with CDK12-deficient refractory metastatic colorectal cancer.

Study Overview

• Status: Not yet recruiting
• Conditions: Colorectal Cancer
• Intervention / Treatment: Drug: Everolimus (Afinitor) tablets

Detailed Description

Metastatic colorectal cancer (mCRC) remains a major cause of cancer-related mortality. Patients with refractory disease who have progressed after standard systemic therapies have limited treatment options and poor clinical outcomes. Identification of molecularly defined subgroups that may benefit from targeted therapeutic strategies represents an important unmet clinical need.

Cyclin-dependent kinase 12 (CDK12) plays a role in transcriptional regulation of genes involved in DNA damage response and genomic stability. CDK12 deficiency has been reported in a small subset of colorectal cancers, estimated at approximately 3-5% of cases. This molecular alteration may confer distinct biological characteristics and potential therapeutic vulnerabilities. However, the clinical efficacy of mTOR inhibition in CDK12-deficient metastatic colorectal cancer has not been prospectively evaluated.

EVER-RECODE adopts a combined Phase Ib/II study design. Phase Ib Component Design: Prospective, multicenter, open-label, single-arm study utilizing a traditional 3+3 dose-escalation design.

Objectives:

• Evaluate the safety and tolerability of everolimus in patients with CDK12-deficient refractory mCRC.
• Determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D).

Planned dose levels include 5 mg/day, 7.5 mg/day, and 10 mg/day administered orally once daily in continuous dosing. Although 10 mg/day has been widely used in several solid tumors, everolimus is associated with dose-dependent toxicities, particularly mucosal and dermatologic adverse events that frequently occur during early treatment. To ensure patient safety in this refractory population, the study adopts 5 mg/day as the starting dose, with stepwise escalation under close safety monitoring to identify the optimal tolerated dose.

Phase II Component Design: Prospective, multicenter, open-label, single-arm expansion study.

Objective:

• Evaluate the preliminary antitumor activity of everolimus at the RP2D in patients with CDK12-deficient refractory mCRC.

Study Procedures Eligible participants must have metastatic colorectal cancer with CDK12 deficiency confirmed by immunohistochemistry (IHC). Participants will receive continuous daily oral everolimus. Radiologic tumor assessments will be performed every 8 weeks. Participants will be followed for safety and survival for up to 24 months.

Primary Endpoints Phase Ib: Incidence of dose-limiting toxicities (DLTs) and determination of MTD/RP2D.

Phase II: Objective response rate (ORR) assessed according to RECIST version 1.1.

• Study Type: Interventional
• Enrollment (Estimated): 38
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Xiangxing Kong; Phone Number: +8615068803769; Email: kongxiangxing@zju.edu.cn
• Study Contact Backup: Name: Jianqing YU; Phone Number: +8619521531205; Email: jianqingyu@zju.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Ability to understand and voluntarily sign an ethics committee-approved informed consent form and willingness to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
2. Age 18 to 80 years (inclusive) at the time of signing informed consent; male or female.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Estimated life expectancy ≥12 weeks.
5. CDK12 deficiency confirmed by immunohistochemistry (IHC).

6. Histologically confirmed metastatic colorectal cancer with documented disease progression after prior standard systemic antitumor therapies, including but not limited to oxaliplatin, fluoropyrimidine, and irinotecan.

   o Patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) tumors must have experienced disease progression following anti-PD-1/PD-L1 therapy.

7. At least one measurable lesion according to RECIST version 1.1, defined as:

   • Non-nodal lesions ≥10 mm in longest diameter by CT scan (slice thickness ≤5 mm);
   • Malignant lymph nodes with short axis ≥15 mm by CT scan (slice thickness ≤5 mm recommended).

8. Adequate organ function meeting all of the following criteria:

   Hematologic (without growth factor support or transfusion within 7 days prior to testing):

   • Absolute neutrophil count ≥1.5 × 10⁹/L
   • Platelet count ≥75 × 10⁹/L
   • Hemoglobin ≥90 g/L

   Biochemical:

   • Total bilirubin ≤1.5 × upper limit of normal (ULN)
   • AST and ALT ≤2.5 × ULN
   • Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min (calculated using Cockcroft-Gault formula)

   Coagulation:

   • International normalized ratio (INR) ≤1.5
   • Activated partial thromboplastin time (aPTT or PTT) ≤1.5 × ULN

9. Absence of high-risk conditions, including:

   • Active or major cardiovascular events within 6 months (e.g., myocardial infarction, severe heart failure, stroke);
   • Severe pulmonary dysfunction requiring long-term oxygen therapy or interstitial lung disease/pulmonary fibrosis;
   • Active uncontrolled infection (including uncontrolled HBV, HCV, HIV, or tuberculosis);
   • Other active malignancies within 5 years, except those treated with curative local therapy.

10. For participants of childbearing potential:

    • Must agree to use effective contraception during the study and for 120 days after completion;
    • Negative serum pregnancy test within 7 days prior to enrollment;
    • Not breastfeeding.

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded:

1. Untreated or active central nervous system (CNS) metastases. Patients with a history of leptomeningeal metastases or current leptomeningeal disease.

2. Receipt of systemic antitumor therapy within 4 weeks prior to initiation of study treatment.

   • For prior small-molecule targeted therapy: the interval between the end of prior therapy and first study dose must be ≥5 half-lives of the drug or ≥7 days, whichever is longer.
   • For prior traditional Chinese antitumor medicines: ≥2 weeks washout is required.
3. Palliative radiotherapy to non-target lesions, radioactive seed implantation, radiofrequency ablation, or similar local therapy within 28 days prior to first study dose.

4. Toxicities or complications from prior therapies that have not recovered to NCI-CTCAE grade ≤1 or to eligibility-specified levels.

   o Patients with stable grade ≤2 toxicities may be enrolled at investigator discretion if no safety risk exists (e.g., immune checkpoint inhibitor-related type 1 diabetes or hypothyroidism controlled with hormone replacement therapy).

5. Within 28 days prior to first study dose: inability to swallow oral medication, chronic diarrhea, active gastroenteritis, gastrointestinal perforation, prior major gastrointestinal resection, colitis, or other conditions that may impair drug administration or absorption.

6. Clinically symptomatic moderate or severe ascites requiring therapeutic paracentesis or drainage within 2 weeks prior to study treatment.

   • Small asymptomatic ascites detected by imaging is allowed.
   • Uncontrolled or moderate-to-large pleural effusion or pericardial effusion.

7. Evidence of intestinal obstruction or signs/symptoms of obstruction at baseline.

   • Patients who underwent surgery with complete resolution of obstruction may be screened.
   • Presence of an indwelling intestinal stent at screening.

8. Uncontrolled or severe cardiovascular disease, including:

   • Severe or unstable congestive heart failure (NYHA class II-IV)
   • Myocardial infarction within 6 months prior to first dose
   • Unstable angina within 1 month prior to treatment
   • Unstable arrhythmia

9. History of or concurrent malignancies other than colorectal cancer, unless in complete remission for ≥5 years prior to screening and not requiring ongoing therapy, except:

   • Basal cell carcinoma of the skin
   • Superficial bladder cancer
   • Cutaneous squamous cell carcinoma
   • Cervical carcinoma in situ
   • Localized prostate cancer
   • Ductal carcinoma in situ after curative surgery
   • Non-metastatic prostate or breast cancer receiving hormone therapy

10. Severe infection within 28 days prior to first dose, including infections requiring hospitalization, bacteremia, or severe pneumonia.

    • Active infection requiring therapeutic intravenous antibiotics within 2 weeks prior to treatment.
    • Prophylactic antibiotics (e.g., for urinary tract infection prevention) are permitted.

11. Active hepatitis B infection defined as:

    o Positive HBsAg AND HBV DNA ≥10,000 copies/mL (≥2,000 IU/mL).

    Active hepatitis C defined as:

    o Positive HCV antibody AND detectable HCV RNA.

12. Active pulmonary tuberculosis within 1 year prior to enrollment, or history of active tuberculosis >1 year prior without appropriate standard treatment.
13. Known immunodeficiency, including HIV positivity, congenital or acquired immunodeficiency disorders, or history of organ transplantation.
14. Active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, myasthenia gravis, or requirement for long-term systemic immunosuppressive therapy.
15. Concomitant use of strong CYP3A4 inhibitors or inducers that cannot be discontinued ≥7 days prior to first dose (e.g., ketoconazole, itraconazole, clarithromycin, rifampin, carbamazepine, phenobarbital).

16. Active severe oral mucosal disease or recurrent oral ulceration.

    o History of ≥grade 2 stomatitis that has not recovered to CTCAE grade ≤1.

17. Active dermatologic disorders (e.g., psoriasis, severe eczema, chronic pruritus) or prior ≥grade 2 drug-related skin reactions not fully resolved.

18. Prior treatment with everolimus and:

    • Development of ≥grade 3 drug-related toxicity, OR
    • Discontinuation due to resistance or lack of efficacy.
19. Known hypersensitivity to everolimus or any of its metabolites.
20. Pregnant or breastfeeding women, or women planning pregnancy during the study period.
21. Uncontrolled psychiatric illness, known alcohol or drug abuse, incarceration, or other conditions that may interfere with study compliance.
22. Any other condition that, in the investigator's judgment, may increase study risk, interfere with study outcomes, or make the participant unsuitable.
23. Inability to understand study conditions and objectives or refusal to sign informed consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Everolimus Treatment; Participants with CDK12-deficient refractory metastatic colorectal cancer will receive oral everolimus once daily. Phase Ib will follow a traditional 3+3 dose-escalation design (5 mg, 7.5 mg, 10 mg, oral, daily) for 8 weeks to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Phase II will evaluate efficacy at the RP2D.	Drug: Everolimus (Afinitor) tablets; Everolimus administered orally once daily in continuous treatment. Phase Ib dose levels include 5 mg/day, 7.5 mg/day, and 10 mg/day using a standard 3+3 dose-escalation design. Phase II participants will receive everolimus at the RP2D determined in Phase Ib.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Dose-Limiting Toxicities (DLTs)	Dose-limiting toxicity (DLT) is defined as treatment-related toxicity occurring within the first 8 weeks (DLT observation window) that is assessed as definitely, probably, or possibly related to everolimus and meets any of the following criteria based on NCI-CTCAE version 5.0: Grade ≥3 non-hematologic toxicity (excluding Grade 3 nausea/vomiting resolving within 48 hours with supportive care, Grade 3 alopecia, and Grade 3 fatigue without ECOG deterioration);; Grade 4 hematologic toxicity (including neutropenia lasting ≥7 days, thrombocytopenia with active bleeding, or hemoglobin <60 g/L requiring urgent transfusion);; Grade 3 hematologic toxicity persisting ≥14 days without recovery to ≤Grade 2;; Treatment interruption ≥14 days due to drug-related toxicity;; Other toxicities considered by the investigator to significantly compromise patient safety. For Phase Ib study	First 8 weeks after initial dose
Objective Response Rate (ORR)	Proportion of participants achieving complete response (CR) or partial response (PR) according to RECIST version 1.1. For Phase II study	Assessed every 8 weeks up to 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D)	Determination of the highest dose level at which ≤1 of 6 participants experiences DLT during the first 8 weeks (3+3 design). For Phase Ib study	Up to 8 weeks
Incidence of Treatment-Emergent Adverse Events (TEAEs)	Incidence and severity of adverse events graded according to NCI-CTCAE version 5.0. For Phase Ib and Phase II study	From first dose until end of treatment (up to 24 months)
Progression-Free Survival (PFS)	Time from first dose to disease progression per RECIST version 1.1 or death from any cause. For Phase II study	Up to 24 months
Overall Survival (OS)	Time from first dose to death from any cause. For Phase II study	Up to 24 months
Disease Control Rate (DCR)	Proportion of participants achieving complete response (CR), partial response (PR), or stable disease (SD) according to RECIST version 1.1.	Assessed every 8 weeks up to 24 months
Duration of Response (DoR)	Time from first documented response (CR or PR) to disease progression or death. For Phase II study	Up to 24 months

Collaborators and Investigators

• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Investigators: Principal Investigator: Xiangxing Kong, Second Affiliated Hospital, School of Medicine, Zhejiang University

Study record dates

Study Major Dates

• Study Start (Estimated): March 1, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: February 22, 2026
• First Submitted That Met QC Criteria: February 22, 2026
• First Posted (Actual): February 27, 2026

Study Record Updates

• Last Update Posted (Actual): February 27, 2026
• Last Update Submitted That Met QC Criteria: February 25, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Colorectal cancer; Everolimus; CDK12
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Intestinal Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colonic Diseases; Colorectal Neoplasms; Organic Chemicals; Pharmaceutical Preparations; Dosage Forms; Macrolides; Lactones; Sirolimus; Everolimus; Tablets
• Other Study ID Numbers: Everolimus-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: In accordance with the requirements of the International Committee of Medical Journal Editors, the de-identified raw data of this study will be made public after the results are published. The access method will be stated when the research results are published.
• IPD Sharing Time Frame: The access method will be stated when the research results are published.
• IPD Sharing Access Criteria: To access the Individual Participant Data (IPD), a detailed data usage plan must be submitted, specifying the research objectives and study content, which will be approved following review by the Principal Investigator (PI) of this study.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No